Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) observed a climb of 6.93% on TUESDAY, trading period with closing price of $332.6. The company’s last traded volume of 2321059 shares vs to an average volume of 680.06K shares. The stock as of last trading session moved at 22.56% from its 52-week low and was trading at -24.75% to its 52-week high.
Regeneron Pharmaceuticals, Inc. (REGN) recently reported that it will share new and updated data for two investigational medicines for blood cancers and a third for a rare blood disease at the 2019 American Society of Hematology (ASH) Yearly Meeting from December 7-10 in Orlando, FL.
“The ASH presentations highlight Regeneron’s growing portfolio in blood cancer and rare diseases, including data from two of our six bispecific antibodies presently in clinical development,” stated David Weinreich, M.D., Senior Vice President, Head of Global Clinical Development and Co-Head of Global Development at Regeneron. “We will also present data on pozelimab, which we are studying in a Phase 2 program in paroxysmal nocturnal hemoglobinuria.”
“We continue to make important progress with REGN1979 and are presently enrolling a potentially registrational Phase 2 trial. At ASH, we plan to share new data with additional patients and longer duration of follow-up, with about 20 patients at effective dose levels for each cohort of follicular lymphoma and diffuse large B-cell lymphoma,” stated Israel Lowy, M.D., PhD, Senior Vice President and Head of Clinical and Translational Sciences for Oncology at Regeneron. “As part of our expanding bispecific portfolio, we will also present encouraging, early single-agent data on REGN5458, our BCMAxCD3 bispecific for multiple myeloma. Additional investigational bi-specific antibodies are predictable to enter clinical trials in the coming year.”
Analyst recommendation for this stock stands at 2.5. The volatility in the previous week has experienced by 2.96% and observed of 2.44% in the previous month. 73.80% ownership is held by institutional investors while insiders hold ownership of 19.40%. In the trailing 12 months period, return on assets ratio of the Company was 17.00% and return on equity ratio was 23.10% while its return on investment ratio was 24.90%. The P/E ratio was recorded at 19.11.